About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Development of New Antibiotics is Slow Despite Increasing Dangers of Superbugs

by Kathy Jones on April 21, 2013 at 8:58 PM
Font : A-A+

 Development of New Antibiotics is Slow Despite Increasing Dangers of Superbugs

The US Food and Drug Administration has approved just one new systemic antibiotic drug since the launch of the 10 x '20 Initiative by the Infectious Diseases Society of America (IDSA) in 2010 despite a desperate shortage of new antibiotics to combat drug resistant bacteria.

In a new report, published online today in Clinical Infectious Diseases, IDSA identified only seven new drugs in development for the treatment of infections caused by multidrug-resistant gram-negative bacilli (GNB) bacteria. GNB, which include the "nightmare bacteria" to which the Centers for Disease Control and Prevention (CDC) alerted the public in its March 2013 Vital Signs www.cdc.gov/media/releases, represent the most pressing medical need. Importantly, there is no guarantee that any of the drugs currently in development to treat GNB will make it across the finish line to FDA approval and none of them will work against the most resistant bugs we're worried about today.

Advertisement

"In the past, the 10 x '20 goal would have been considered modest, but today the barriers to approval of nine additional antibiotics by 2020 seem insurmountable," said Henry Chambers, MD, chair of IDSA's Antimicrobial Resistance Committee (ARC). "Some progress has been made in the development of new antibiotics, but it's not nearly enough, and we absolutely must accelerate our efforts."

"We're losing ground because we are not developing new drugs in pace with superbugs' ability to develop resistance to them. We're on the precipice of returning to the dark days before antibiotics enabled safer surgery, chemotherapy and the care of premature infants. We're all at risk," said Helen W. Boucher, MD, lead author of the policy paper and a member of IDSA's Board of Directors and ARC.
Advertisement

Entitled "10 x '20 Progress: Development of New Drugs Active against Gram-negative Bacilli: An Update from the Infectious Diseases Society of America," the paper outlines actions that must be taken to address the synergistic crises of an anemic antibiotic pipeline coupled with an explosion in multi-drug resistant pathogens. A multi-pronged approach is needed, including new economic incentives to encourage antibiotic research and development (R&D); clarification of FDA's requirements for antibiotic approval; increased research funding; improved infection prevention; and new public health efforts including better data collection and surveillance of drug resistance and use of antibiotics. We also need to encourage "antibiotic stewardship," which includes measures that health care facilities, providers and even patients can take to preserve the life-saving power of antibiotics by limiting their inappropriate use.

IDSA leaders have been exploring with other stakeholders specific solutions to address the pipeline problem including the creation of a Limited Population Antibacterial Drug (LPAD) approval pathway to speed drugs to approval as well as new R&D tax credits and reimbursement models. Congressional Republican leaders in the U.S. House of Representatives announced last month their intent to make fixing the antibiotic R&D pipeline a priority for the energycommerce.house.gov.

Ironically, at this urgent time of greatest need, the number of pharmaceutical companies investing in antibiotic R&D has plummeted. Pharmaceutical companies typically put R&D resources into the development of chronic disease drugs - including those to treat high cholesterol, diabetes, and cancer - which provide significant financial rewards, partly because they are intended to be taken for long periods of time. Antibiotics, which are intended to be taken for short courses, just can't compete. The results are playing out in real time, with the smaller pharmaceutical company Polymedix - which has one of the seven drugs in development noted in the 10 x '20 paper - filing for bankruptcy protection in early April 2013. Moreover, the policy update reports that only four large multinational companies remain in antibiotic R&D. One of these, AstraZeneca, which has two of the seven drugs in development, plans to reduce its future investments in antibiotics, its CEO, Pascal Soriot, recently announced. The current pipeline of antibiotics is fragile indeed, and the dwindling roster of antibiotic developers has dire consequences for public health, patient care and national security.

New antibiotics are critically necessary to save the lives of people such as Josh Nahum, a healthy 27-year-old man who died from an overwhelming Enterobacter aerogenes infection as he was recovering in the hospital after a skydiving accident. Although his doctors tried desperately to save Josh, they ran out of antibiotics to treat this virulent bug. Read more about Josh's story and the experiences of others whose lives have been devastated by antibiotic resistance:idsociety.org/Joshs_Story.aspx">http://www.idsociety.org/Joshs_Story.aspx.

IDSA first warned of the looming antibiotic apocalypse with its 2004 report, Bad Bugs, No Drugs. Nearly 50 other medical societies and organizations, including the American Medical Association, have endorsed the 10 x '20 initiative so far.

"IDSA is committed to ensuring proper use of currently-available antibiotics to make certain we can continue to count on them. But that is not enough. Simply put, the antibiotic pipeline is on life support and novel solutions are required to resuscitate it - now," said IDSA President David A. Relman, MD. "In the past year, the heads of CDC and the World Health Organization, along with the United Kingdom's chief medical officer, have all sounded the alarm about rising rates of antibiotic resistance. The lack of new antibiotics to treat these potentially life-threatening infections signals the end of modern medicine as we know it."



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Guide to Brushing Your Teeth the Right Way
Resting Heart Rate
Is COVID-19 Vaccination during Pregnancy Safe?
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
MRSA - The Super Bug Antibiotics Eye Infections Natural Antibiotics to Fight Bacterial Infections Vancomycin-Resistant Enterococci (VRE) Boils - Treatment by Drugs Multiple Drug Allergy Syndrome Interaction of Antibiotics with Dairy Products Antibiotic Resistance - An Emerging Global Crisis 

Recommended Reading
Drug Resistance - Antibiotic Resistance
Drug resistance is often a problem in malaria, tuberculosis, HIV, sexually transmitted diseases and ...
Typhoid and Paratyphoid Enteric Fevers
Typhoid and Paratyphoid Enteric Fevers are caused by bacteria called Salmonella typhi. Causes, ......
Screening Tests for Tuberculosis
Tuberculin skin test and Interferon - Release Assays are tests used to screen for tuberculosis....
Antibiotic Resistance - An Emerging Global Crisis
Antibiotic resistance refers to the adaption of bacteria that allows them to grow even in the presen...
Antibiotics
Antibiotics are among the most used and abused medications. This article explains some general featu...
Boils - Treatment by Drugs
Diabetes patients have reduced immunity, which makes them more susceptible to skin infections like b...
Eye Infections
Eye infection is a common problem that often causes pain and discomfort to the eyes. Common symptoms...
Interaction of Antibiotics with Dairy Products
Antibiotics like tetracyclines and fluoroquinolones used in the treatment of bacterial infections in...
MRSA - The Super Bug
MRSA infection is the most dreaded hospital or community acquired infection that can become ......
Multiple Drug Allergy Syndrome
Multiple drug allergy syndrome or multiple drug hypersensitivity syndrome is a condition that causes...
Natural Antibiotics to Fight Bacterial Infections
Fighting infections the natural way and preventing them is always more effective than consuming medi...
Vancomycin-Resistant Enterococci (VRE)
Enterococci are a group of gram-negative bacteria that mostly inhabit the human gut. At present ther...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use